ABCELLERA BIOLOGICS INCABCL
ASignal's systematic analysis rates ABCL as Neutral.
Reflects the latest available analysis · analyzed Oct 3, 2026
The case on ABCL
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong financial health score (0.9)
- Low debt-to-equity ratio (0.15x)
- High current and quick ratios indicating strong liquidity
- MACD above signal line suggesting bullish momentum
- Price trading above 20-day and 50-day moving averages
- Overbought RSI at 72.82
- Negative gross, operating, and net margins
- Negative free cash flow
- High price-to-sales ratio (67.29x)
- Negative year-over-year revenue growth (-76.3%)
- No Reddit mentions indicating low retail interest
See the full verdict on ABCL
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes ABCL
Most investors never get a second opinion, let alone several. ASignal runs ABCL past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.